U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on its website LillyDirect, with shipments starting in early August.
The company said the 12.5 milligrams and 15 mg doses of the drug will be available for US$499 per month on the website with shipments to self-paying patients.
- Multiple milk brands in Canada recalled over risk of ‘pieces of glass’
- Spike in cost of diesel threatens consumer wallets, global supply chain: experts
- Left out of Manitoba budget, North End treatment plant funding faces questions
- If Iran war were to end, how soon would you feel relief at the gas pumps?
-
![]()
Canadian retirees earning over $100,000 don’t need old age security cheques, advocacy group says -
![]()
Alberta family gets back $40K from dealership after new truck seized for being stolen -
![]()
Home organizing tips for pet owners to keep spaces clean and calm -
![]()
New non-profit supports Vancouver’s small business community
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, the company added.
Lilly began offering vials of the two lowest doses of Zepbound, typically sold in auto-injector pens, in August last year.
In February, the company started offering the vials at a discount.
Comments
Want to discuss? Please read our Commenting Policy first.